796848-79-8

Basic information

• Product Name: 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea
• Synonyms: 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea;N-(2-chloro-4-hydroxyphenyl)-N'-cyclopropyl-Urea;Urea, N-(2-chloro-4-hydroxyphenyl)-N'-cyclopropyl-;Lenvatinib Impurity a;(Z)-N-(2-chloro-4-hydroxyphenyl)-N-cyclopropylcarbamimidic acid;Lenvatinib Impurity 6;lenvaint-I
• CAS NO: 796848-79-8
• Molecular Formula: C10H11ClN2O2
• Molecular Weight: 226.65954
• Mol File: 796848-79-8.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 364.6±42.0 °C(Predicted)
• Appearance: /
• Density: 1.43±0.1 g/cm3 (20 oC 760 Torr), Calc.*
• Storage Temp.: 2-8°C
• PKA: 9.37±0.31(Predicted)
• CAS DataBase Reference: 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea(796848-79-8)
• EPA Substance Registry System: 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea(796848-79-8)

Safety Data

• Hazardous Substances Data: 796848-79-8(Hazardous Substances Data)

Usage

Uses

Desquinolinyl Lenvatinib is a metabolite of Lenvatinib (L329400) which is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors.

Upstream product

• 52671-64-4 4-Amino-3-chlorophenol hydrochloride 
• 1885-14-9 phenyl chloroformate 
• 765-30-0 Cyclopropylamine 
• 4333-56-6 cyclopropyl bromide 
• 17609-80-2 4-amino-3-chlorophenol 
• 1033090-34-4 N-cyclopropyl-1H-imidazole-1-carboxamide 
• 796848-80-1 phenyl N-(2-chloro-4-hydroxyphenyl)carbamate 

Downstream Products

• 417722-93-1 4?(4?amino?3?chlorophenoxy)?7?methoxyquinoline?6?carboxamide 

Relevant articles and documents

UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF

The present invention relates to a urea-substituted aromatic ring-linked dioxane-quinazoline compound of Formula (I) and a urea-substituted aromatic ring-linked dioxane-quinoline, or a pharmaceutically acceptable salt thereof or a hydrate thereof. Also provided are the preparation of the compound as shown in Formula (I) and the pharmaceutically acceptable salt thereof and the use thereof as a drug. The drug is used as an inhibitor of tyrosine kinases (e.g., VEGFR-2, C-RAF, B-RAF) for treating tyrosine kinase-related diseases.

Isotope enrichment lenvatinib

The invention discloses isotope enrichment lenvatinib, a pharmaceutically acceptable salt form thereof, and a treatment method using the isotope enrichment lenvatinib, and specifically relates to an isotope enrichment compound represented by a formula I o

A [...] synthetic method

The invention provides a method of synthesizing [...]. First of all the invention to 4 - cyano - 3 - hydroxy aniline as the starting material, by dimethyl carbonate methylation, after third acid in the oximation reaction at room temperature, the conditions in the PPA shut-ring forms the 6 - cyano - 7 - methoxy - 4 - quinolinone, in thionyl chloride formed under the action of the 6 - cyano - 7 - methoxy - 4 - [...], under acidic conditions [...] cyano hydrolysis synthesis of one of the intermediates 6 - formamido - 7 - methoxy - 4 - chloroquinolin. Then the 4 - hydroxy - 2 chloroaniline with cyanogen bromide at low temperature 4 - hydroxy - 2 - chloro cyaniding amine, the 4 - hydroxy - 2 - chloro cyaniding amine with bearing-displacement generating Reeth reaction synthesis [...] another key intermediate 1 - (2 - chloro - 4 - hydroxy-phenyl) - 3 - ring propyl urea. Finally the two intermediate 6 - formamido - 7 - methoxy - 4 - chloroquinolin and 1 - (2 - chloro - 4 - hydroxy-phenyl) - 3 - ring propyl urea in the alkaline environment for carrying out the alkylation reaction [...]. This scheme has mild reaction conditions, no highly toxic reagent, environmental protection and the like.